Humanetics Corporation   Report issue

For profit Phase 2
Founded: Minneapolis MN United States (1988)

Organization Overview

First Clinical Trial
2007
NCT00470418
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Humanetics Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Radiation Syndrome (Phase 1)

Alzheimer Disease (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Dementia (Phase 2)

Pulmonary Fibrosis (Phase 2)

Radiation Injuries (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6